# A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

> **NCT00628303** · PHASE3 · WITHDRAWN · sponsor: **MedImmune LLC**

## Conditions studied

- Wheezing

## Interventions

- **BIOLOGICAL:** Motavizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00628303
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-10
- **Primary completion:** 2011-02
- **Final completion:** 2011-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never officially opened for enrollment
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628303, "A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00628303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*